United Kingdom· GB-APID-35820711000001107
Crysvita 10mg/1ml solution for injection vials
A burosumab product containing burosumab, registered in United Kingdom by Kyowa Kirin Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Burosumab is registered in 14 of 19 countries.
Countries holding a registration under ATC M05BX05 (burosumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Burosumab · ATC M05BX05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Burosumab
- Manufacturer
- Kyowa Kirin Ltd
- Country
- United Kingdom (GB)
- ATC code
- M05BX05
- ATC class
- Burosumab
- Defined daily dose
- 2.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5038903001928
- gtin5038903001713
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
11 interactions on record for burosumab.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Burosumab · interactions on record
11 records
- 9 severe
- 2 moderate
Most severe, free to view
- DihydrotachysterolA11CC02severe
- CalcitriolA11CC04severe
- CalcifediolA11CC06severe
- ParicalcitolA11CC07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Burosumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCrysvita 10 mgKyowa Kirin Holdings
- CzechiaCRYSVITAKyowa Kirin Holdings B.V., Hoofddorp
- SpainCRYSVITA 10 MG SOLUCION INYECTABLEKyowa Kirin Holdings B.V.
- SwedenCRYSVITA 10 mg Injektionsvätska, lösningKyowa Kirin Holdings B.V.
- NorwayCrysvitaKyowa Kirin Holdings B.V.
- PolandCRYSVITAKyowa Kirin Holdings B.V.
- FinlandCrysvitaKyowa Kirin Holdings B.V.
- Japanブロスマブ（遺伝子組換え）協和キリン
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Crysvita
- Liechtenstein · Crysvita
- Norway · Crysvita
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/32448100-f5ea-4386-b61a-c07b966710c6 GET /v1/drugs/32448100-f5ea-4386-b61a-c07b966710c6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "35820711000001107",
"desc": "Crysvita 10mg/1ml solution for injection vials (Kyowa Kirin Ltd)",
"form": "Solution for injection",
"vpid": "35820511000001102",
"source": "dmd",
"vtm_id": "774941002",
"strength": "10 mg",
"substance": "Burosumab",
"ingredient": "Burosumab",
"supplier_code": "3558501000001106"
}See everything about burosumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.